Baricitinib for Low Platelet Counts After Bone Marrow Transplant
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests whether a medication called baricitinib can help patients whose platelet counts remain dangerously low after a bone marrow transplant, even after standard treatments. Platelets are blood cells that help stop bleeding, and this study aims to see if baricitinib can restore them.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You had an allogeneic bone marrow or stem cell transplant (from a donor)
- Your platelet count has stayed below 20,000 or you need regular blood transfusions, despite 4+ weeks of standard medications
- You have 'complete donor chimerism' (your new bone marrow is fully working and the donor's blood cells are fully established)
- You don't have active infections, active graft-versus-host disease, cancer relapse, or severe organ problems
- You haven't received a live vaccine in the past 12 weeks and won't during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
This trial tests a pill called baricitinib to see if it helps people recover from lung injury after a brain bleed. It is for patients who need a breathing machine due to ARDS that started within a week of the bleed.
This trial tests whether adding baricitinib (a type of immune-modulating drug) to a standard platelet-boosting medication works better than the standard medication alone for adults with chronic ITP that hasn't responded to initial treatment. It aims to find a new option for people whose platelet counts remain low despite treatment.
This trial studies whether avatrombopag can help your platelet count recover after a bone marrow transplant from an unrelated donor (UCBT) in certain bone marrow failure diseases. If platelets recover better, it may reduce risks related to low platelets after transplant.
This trial tests whether a one-time infusion of umbilical cord blood cells can safely raise platelet counts in people whose counts dropped after cancer treatment. It is for patients whose low platelets are clearly linked to their cancer therapy and who have no other major health problems.
This trial tests if baricitinib, an anti-inflammatory drug, can help people with bleeding in the brain from a head injury. It is for adults with moderate to severe traumatic brain injury who are not immediately having surgery.
Hear when a new Allogeneic Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.